Journal of Cancer Survivorship

, Volume 2, Issue 3, pp 128-137

First online:

Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors

  • H. S. HaugnesAffiliated withDepartment of Oncology, Institute of Clinical Medicine, University of Tromsø Email author 
  • , N. AassAffiliated withDepartment of Oncology, Rikshospitalet Medical Center
  • , S. D. FossåAffiliated withDepartment of Clinical Cancer Research, Rikshospitalet Medical CenterMedical Faculty, University of Oslo
  • , O. DahlAffiliated withSection of Oncology, Institute of Medicine, University of BergenDepartment of Oncology, Haukeland University Hospital
  • , O. KleppAffiliated withDepartment of Oncology, St. Olav University Hospital
  • , E. A. WistAffiliated withDepartment of Oncology, Ullevål University Hospital
  • , T. WilsgaardAffiliated withInstitute of Community Medicine, University of Tromsø
  • , R. M. BremnesAffiliated withDepartment of Oncology, Institute of Clinical Medicine, University of TromsøDepartment of Oncology, University Hospital of North Norway

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



We examined if testicular cancer (TC) treatment is associated with any risk for cardiovascular morbidity or predicted mortality according to the SCORE model, in which a 10-year future risk of ≥5% for developing a fatal cardiovascular event qualify for high-risk status.


One thousand one hundred thirty-four TC survivors treated 1980–1994 participated in this study (1998–2002). Patients were categorised in four treatment groups: surgery (n = 225), radiotherapy (n = 445), and two chemotherapy groups: cumulative cisplatin dose ≤850 mg (n = 375) and >850 mg (cis>850, n = 89). Patients with cardiovascular disease, diabetes or SCORE ≥5% constituted a high-risk group, and those with SCORE >1% an intermediate/high risk group.


Age-adjusted mean SCORE was 0.93% for the surgery group. In comparison, chemotherapy treated patients had significantly higher SCORE (1.07%, p = 0.01). Only 15% of patients were scored to be at high-risk, while 53% qualified for the intermediate/high risk group. Patients in the cis>850 group had increased odds for having intermediate/high risk, compared with the surgery group (OR 3.4, 95% CI 1.3–8.7). Only 23 cardiovascular events had occurred since the testicular cancer diagnosis.


The SCORE model indicates that patients treated with cisplatin-based chemotherapy have a significantly increased future risk of a fatal cardiovascular event.

Implications for cancer survivors

TC survivors should be followed regularly with respect to cardiovascular risk profile beyond the routine 10-year clinical follow-up.


Testicular cancer Cisplatin Cardiovascular Mortality Morbidity SCORE